Integrating Cell Line and CMC Development

Alloy Therapeutics | Cell Line Development | CHO | Clone Selection | Open-Source Manufacturing | Portable CMC | Q2 2022 | Transposons | Wheeler Bio

Stephen Hamilton, Ph.D.
Chief Technical Officer, Wheeler Bio
Dr. Hamilton has over 20 years of industrial and academic research experience delivering on key technical milestones in both small biotech and large pharma environments. He has an extensive track record of leading successful platform and product development projects resulting in numerous regulatory filings and patent awards. Across the span of his career, he co-authored over 25 research articles, including two first author manuscripts in the journal Science. His technical expertise is in protein production, glycobiology and host cell engineering, and his areas of interest are in innovation and technology development around optimized workflows and new product development. He completed his postdoctoral research at Dartmouth Medical School in Hanover, NH. Steve earned a Ph.D. in biochemistry and molecular biology from the University of Leeds, UK, and a B.Sc. in biochemistry from Heriot-Watt University in Edinburgh, UK.